This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it’s a good time to correct one of the more egregious misconceptions regarding the handling of patient subgroup data that has been floating persistently around the internet.
I’m referring specifically to what Cassava can, and cannot, do with data from roughly 70% of 800 participants in the RETHINK-ALZ-52 study with mild Alzheimer’s. The remaining 30% of participants entered the study with moderate disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in